NCT00209716View on ClinicalTrials.gov

Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Esophageal Cancer
Interventions
DRUG

Taxotere

30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.

DRUG

5-Fluorouracil

800 mg/m2, CIV (CIV.in the vein) on day 1\~5 of each 28 day cycle.

DRUG

Briplatin

15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle.

Trial Locations (1)

060-8638

・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo

All Listed Sponsors
collaborator

Hokkaido University Hospital

OTHER

lead

Hokkaido Gastrointestinal Cancer Study Group

OTHER

NCT00209716 - Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer. | Biotech Hunter | Biotech Hunter